LLPA
5.5.2021 15:02:09 CEST | Business Wire | Press release
The Leading Learning Partners Association (LLPA), an international association of 32 members across 55+ countries, have successfully hosted a series of C3 cloud skills tour events in over 17 countries in a virtual setting since January 2021.
We recognize that transformation to cloud technologies requires skills transformation and most importantly, that digital transformation is about people. During this event, The LLPA in close cooperation with Microsoft and other key partners provide business leaders, executives, IT professionals, developers and Microsoft Azure consultants, an opportunity to gain valuable insights and learn from local and international leading industry experts on topics such as building high-performance teams and better ways of leveraging existing and future cloud investments. This exciting global tour is famous for bringing learning thought leaders, executives, and partners, together to collaborate and share best practices.
“Leading transformation starts with an idea, a vision and the ability to identify expectations. For this you must be informed, knowledgeable, and equipped. The sphere of cloud technology is robust and ever changing. We’re inviting IT professionals and leaders everywhere, to attend the final C3 Global Cloud Skills Tour event to gain knowledge from leading experts that will help organizations of all sizes build a future-ready workforce” says Patrick Kersten, Chairman of the Board at LLPA.
“Contrary to popular belief, digital transformation is less about technology and more about people. You can pretty much buy any technology, but your ability to adapt to an even more digital future depends on developing the next generation of skills, closing the gap between talent supply and demand, and future-proofing your own and others’ potential” – Harvard Business Review. The C3 Global Cloud Skills Tour aims to address the cloud skills gaps by ensuring all existing and future cloud customers have the technical and soft skills needed to be successful.
The LLPA will host this live 2-day event 9-10 June 2021 from 9-1pm CET joined by international speakers, Ken Taylor , President – Training Industry, Inc., Kåre Nygård , Head of Digital Consulting Norway – TietoEVRY, Mohanna Azarmandi , Chief Learning Officer – Microsoft, Jayne Groll , CEO – DevOps Institute and many others. The LLPA have more than 15 live and on-demand sessions planned, ranging from technical deep dives to digital transformation and skilling best practice sessions. We also have a great panel discussion lined up led by leading training providers from multiple regions.
“We need to adjust and embrace a more virtual way of living and more than ever it is vital that people remain closely connected. It is great to see that the global network of the Leading Learning Partner Association is showing leadership to deliver 100% virtual trainings to support our mutual customers in the continuation and acceleration of their skilling efforts to support their digital transformation strategy. These efforts have been recognized by our mutual customers and Microsoft awarded the Leading Learning Partners Association with a global Learning Partner of the year award, for their continuous commitment for accelerating cloud skills.” – Geoff Hirsch, Senior Director of Partner Channel, WW Learning & Readiness at Microsoft.
About The LLPA
Born in the Netherlands in 2013, the Leading Learning Partners Association (LLPA) is a global organization with a member presence in more than 55 countries. Our mission is to be THE global cloud skills services organization, dedicated to providing the right tools, learning resources and services at the right time to ensure cloud skills are accessible to anyone and everyone at any time across the globe.
Our extensive network of trusted members contributes to the development of expert job-ready industry professionals through hybrid learning offerings, consulting, and certification. Together, our members have trained over 500,000 students per year, covering more than 90% of the European GDP. The LLPA has been a Microsoft Partner since 2013 and awarded Microsoft Learning Partner of the Year 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005442/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
